Advertisement

Improving Anemia in Inflammatory Bowel Disease: Impact of the Anemia Care Pathway

  • Talha Qureshi
  • T. Peter Nguyen
  • Ruifei Wang
  • Diana Willis
  • Rajesh Shah
  • Jason K. HouEmail author
Original Article
  • 30 Downloads

Abstract

Background

Anemia is a common complication of inflammatory bowel disease (IBD). Despite existing guidelines for anemia in IBD, it is frequently under-treated and the prevalence of anemia has remained high. To address this gap, the Crohn’s and Colitis Foundation developed the Anemia Care Pathway (ACP).

Aims

To implement the ACP in a managed care setting and identify where it improves practice habits and where barriers remain.

Methods

The ACP was implemented from July 2016 through June 2017 and retrospectively studied. Run charts were used to identify shifts in iron deficiency screening and treatment as well as anemia prevalence. Results were compared to those of other providers in the same center not using the ACP.

Results

640 IBD encounters were studied. In the ACP clinic (n = 213), anemics received iron therapy in only 30% of encounters at baseline but improved to 80%. Concurrently, anemia prevalence decreased from 48 to 25%. Screening for iron deficiency, however, did not improve. No shifts were seen in the non-ACP clinics (n = 427) across the same period despite awareness of the ACP and other guidelines.

Conclusions

Across 1 year, we observed gaps in the screening and treatment of anemia in IBD. Although screening rates did not improve, the ACP appeared to reduce missed opportunities for iron therapy by about half. Most importantly, this was associated with an overall decrease in anemia prevalence. Future refinements to the ACP should be focused on enhanced screening and follow-up.

Keywords

Anemia Iron therapy Iron deficiency Inflammatory bowel disease Anemia care pathway 

Notes

Author’s contribution

JKH contributed to study design, data analysis, and authorship of manuscript. He has approved of the final draft submitted; TQ contributed to authorship, data analysis, and editorial input of the manuscript. He has approved of the final draft submitted; TPN contributed to authorship, data analysis, and editorial input in the manuscript. He has approved of the final draft submitted. RW contributed to editorial input in the manuscript. He has approved of the final draft submitted. DW contributed to editorial input in the manuscript. She has approved of the final draft submitted. RS contributed to editorial input in the manuscript. He has approved of the final draft submitted.

Funding

The research reported here was supported in part with resources at the VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413), at the Michael E. DeBakey VA Medical Center, Houston, TX (JKH).

Compliance with ethical standards

Conflict of interest

JH has served as a speaker for Abbvie, Janssen, served as a consultant for Pfizer, Janssen, Daichii Sankyo, and Abbvie. JH has received research funding from Abbvie, Janssen, Pfizer, Celgene, Eli-Lilly, and Redhill Biopharma. TQ, TN, RW, DW, RS have no financial disclosures.

Ethical considerations

The institutional review boards of the Baylor College of Medicine and Michael E. DeBakey VA Medical Center in Houston, Texas, approved this study.

Supplementary material

10620_2019_5559_MOESM1_ESM.pptx (62 kb)
Supplementary material 1 (PPTX 62 kb)
10620_2019_5559_MOESM2_ESM.pptx (116 kb)
Supplementary material 2 (PPTX 116 kb)

References

  1. 1.
    Filmann N, Rey J, Schneeweiss S, et al. Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis. Inflamm Bowel Dis. 2014;20:936–945.CrossRefGoogle Scholar
  2. 2.
    Fiorino G, Allocca M, Danese S. Commentary: anaemia in inflammatory bowel disease–the most common and ignored extra intestinal manifestation. Aliment Pharmacol Ther. 2014;39:227–228.CrossRefGoogle Scholar
  3. 3.
    Gasche C. Complications of inflammatory bowel disease. Hepatogastroenterology. 2000;47:49–56.Google Scholar
  4. 4.
    Bager P, Befrits R, Wikman O, et al. High burden of iron deficiency and different types of anemia in inflammatory bowel disease outpatients in Scandinavia: a longitudinal 2-year follow-up study. Scand J Gastroenterol. 2013;48:1286–1293.CrossRefGoogle Scholar
  5. 5.
    Gisbert JP, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1299–1307.CrossRefGoogle Scholar
  6. 6.
    Wells CW, Lewis S, Barton RJ, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12:123–130.CrossRefGoogle Scholar
  7. 7.
    Graff LA, Vincent N, Walker JR, et al. A population-based study of fatigue and sleep difficulties in inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:1882–1889.CrossRefGoogle Scholar
  8. 8.
    Bager P, Befrits R, Wikman O, et al. Fatigue in out-patients with inflammatory bowel disease is common and multifactorial. Aliment Pharmacol Ther. 2012;35:133–141.CrossRefGoogle Scholar
  9. 9.
    Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010;7:599–610.CrossRefGoogle Scholar
  10. 10.
    Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013;369:448–457.CrossRefGoogle Scholar
  11. 11.
    WHO U, UNU. Iron Deficiency Anemia: Assessment, Prevention and Control. Report of a Joint WHO/UNICEF/UNU Consultation. Geneva, Switzerland: World Health Organization 2001.Google Scholar
  12. 12.
    Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011–1023.CrossRefGoogle Scholar
  13. 13.
    Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436–2448.CrossRefGoogle Scholar
  14. 14.
    Nielsen OH, Ainsworth M, Coskun M, Weiss G, et al. Management of iron-deficiency anemia in inflammatory bowel disease: a systematic review. Medicine (Baltimore). 2015;94:e963.CrossRefGoogle Scholar
  15. 15.
    Nairz M, Schroll A, Demetz E, Tancevski I, Theurl I, Weiss G. Ride on the ferrous wheel’–the cycle of iron in macrophages in health and disease. Immunobiology. 2015;220:280–294.CrossRefGoogle Scholar
  16. 16.
    Patel D, Trivedi C, Khan N. Management of Anemia in patients with inflammatory bowel disease (IBD). Curr Treat Options Gastroenterol. 2018;16:112–128.CrossRefGoogle Scholar
  17. 17.
    Kaitha S, Bashir M, Ali T. Iron deficiency anemia in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2015;6:62–72.CrossRefGoogle Scholar
  18. 18.
    Stein J, Dignass AU. Management of iron deficiency anemia in inflammatory bowel disease—a practical approach. Ann Gastroenterol. 2013;26:104–113.Google Scholar
  19. 19.
    Hou JK, Gasche C, Drazin NZ, et al. Assessment of gaps in care and the development of a care pathway for anemia in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2017;23:35–43.CrossRefGoogle Scholar
  20. 20.
    Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13:1545–1553.CrossRefGoogle Scholar
  21. 21.
    Kinsman L, Rotter T, James E, Snow P, Willis J. What is a clinical pathway? Development of a definition to inform the debate. BMC Med. 2010;8:31.CrossRefGoogle Scholar
  22. 22.
    Tessier JE, Rupp G, Gera JT, DeHart ML, Kowalik TD, Duwelius PJ. Physicians with defined clear care pathways have better discharge disposition and lower cost. J Arthroplasty. 2016;31:54–58.CrossRefGoogle Scholar
  23. 23.
    Forsmo HM, Pfeffer F, Rasdal A, et al. Compliance with enhanced recovery after surgery criteria and preoperative and postoperative counselling reduces length of hospital stay in colorectal surgery: results of a randomized controlled trial. Colorectal Dis. 2016;18:603–611.CrossRefGoogle Scholar
  24. 24.
    Bradywood A, Farrokhi F, Williams B, Kowalczyk M, Blackmore CC. Reduction of inpatient hospital length of stay in lumbar fusion patients with implementation of an evidence-based clinical care pathway. Spine (Phila Pa 1976). 2017;42:169–176.CrossRefGoogle Scholar
  25. 25.
    Taylor MJ, McNicholas C, Nicolay C, Darzi A, Bell D, Reed JE. Systematic review of the application of the plan-do-study-act method to improve quality in healthcare. BMJ Qual Saf. 2014;23:290–298.CrossRefGoogle Scholar
  26. 26.
    Satsangi J, Silverberg MS, Vermeire S, Colombel J. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753.CrossRefGoogle Scholar
  27. 27.
    Perla RJ, Provost LP, Murray SK. The run chart: a simple analytical tool for learning from variation in healthcare processes. BMJ Qual Saf. 2011;20:46–51.CrossRefGoogle Scholar

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2019

Authors and Affiliations

  • Talha Qureshi
    • 1
    • 3
  • T. Peter Nguyen
    • 4
  • Ruifei Wang
    • 4
  • Diana Willis
    • 1
  • Rajesh Shah
    • 1
    • 2
  • Jason K. Hou
    • 1
    • 2
    • 5
    Email author
  1. 1.Michael E. DeBakey Veterans Affairs Medical CenterHoustonUSA
  2. 2.Section of Gastroenterology and Hepatology, Gastroenterology Division, Department of Internal MedicineBaylor College of MedicineHoustonUSA
  3. 3.Department of MedicineBaylor College of MedicineHoustonUSA
  4. 4.School of MedicineBaylor College of MedicineHoustonUSA
  5. 5.Center for Innovations in Quality, Effectiveness and Safety (IQuESt)Michael E. DeBakey Veterans Affairs Medical CenterHoustonUSA

Personalised recommendations